Personalized treatment plans for people with severe asthma
Tests a personalized treatment plan based on each patient's treatable asthma features against routine care.
Plain-language title generated from the registry record
Registry title: The Study About the Identification of Treatable Traits of Severe Asthma and the Construction of Personalized Treatment System
Key facts
- Where
- Beijing, Changsha, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, and Zhengzhou, ChinaSee the 10 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07136025, who can take part
Where in China
- Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical UniversityBeijing, ChinaTaking people
- Beijing Tiantan Hospital Affiliated to Capital Medical UniversityBeijing, ChinaTaking people
- China-Japan Friendship HospitalBeijing, ChinaTaking people
- The Second Xiangya Hospital of Central South UniversityChangsha, ChinaTaking people
- The First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, ChinaTaking people
- The Second Affiliated Hospital of Zhejiang University School of MedicineHangzhou, ChinaTaking people
- The First Affiliated Hospital of Guangzhou Medical UniversityShanghai, ChinaTaking people
- The First Affiliated Hospital of China Medical UniversityShenyang, ChinaTaking people
- Shanxi Bethune HospitalTaiyuan, ChinaTaking people
- Henan Provincial People's HospitalZhengzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Chao Yang Hospital
- Trial code
- NCT07136025
- Record updated
- 22 August 2025
- Original description
Severe asthma is a complex and heterogeneous disease. Patients with severe asthma can present with different types of airway inflammation, and are often accompanied by a variety of comorbidities and risk factors. Identification of potentially modifiable factors affecting prognosis, that is, "treatable characteristics", and individualized bundle management based on these characteristics may help to improve the quality of life of patients with asthma and improve the level of asthma control. Through joint research, this project aims to evaluate the treatable characteristics of asthma in patients with severe asthma in tertiary hospitals across the country, including lung function, fractional exhaled nitric oxide, blood routine, allergen IgE, chest CT, and a detailed questionnaire. The distribution of treatable characteristics of patients with severe asthma and its impact on the quality of life or asthma control level of patients were investigated. For patients with severe asthma, multidisciplinary consultation and shared decision-making were used to establish an individualized bundle management model based on the treatable characteristics of severe asthma. A 6-month randomized parallel controlled clinical trial was conducted to determine whether this model was superior to conventional management in improving the quality of life or asthma control in patients with severe asthma. The implementation of this project will build a new model of individualized management of severe asthma based on treatable characteristics and improve the management level of severe asthmaRead full original descriptionShow less
The Study About the Identification of Treatable Traits of Severe Asthma and the Construction of Personalized Treatment System
Severe asthma is a complex and heterogeneous disease. Patients with severe asthma can present with different types of airway inflammation, and are often accompanied by a variety of comorbidities and risk factors. Identification of potentially modifiable factors affecting prognosis, that is, "treatable characteristics", and individualized bundle management based on these characteristics may help to improve the quality of life of patients with asthma and improve the level of asthma control. Through joint research, this project aims to evaluate the treatable characteristics of asthma in patients with severe asthma in tertiary hospitals across the country, including lung function, fractional exhaled nitric oxide, blood routine, allergen IgE, chest CT, and a detailed questionnaire. The distribution of treatable characteristics of patients with severe asthma and its impact on the quality of life or asthma control level of patients were investigated. For patients with severe asthma, multidisciplinary consultation and shared decision-making were used to establish an individualized bundle management model based on the treatable characteristics of severe asthma. A 6-month randomized parallel controlled clinical trial was conducted to determine whether this model was superior to conventional management in improving the quality of life or asthma control in patients with severe asthma. The implementation of this project will build a new model of individualized management of severe asthma based on treatable characteristics and improve the management level of severe asthma
Inclusion: Age ≥18 years, and <80 years with a definite diagnosis of asthma for at least 6 months; Patients met the 2024 GINA criteria for severe asthma, which was defined as "uncontrolled" asthma (frequent asthma symptoms, or frequent acute exacerbations) despite high-dose inhaled corticosteroids (ICS) plus long-acting β2-receptor antagonists (LABAs), or worsening of symptoms after slight tapering of high-dose therapy; They were willing to accept multi-disciplinary and multi-dimensional evaluation and signed informed consent; Informed consent was obtained and patients were able to participate in the study and 6-month follow-up according to the protocol.
Exclusion: Chest surgery or abdominal surgery in the past 3 months; Eye surgery had been performed within the past 3 months; Myocardial infarction within the previous 3 months; Macrolide use within 4 weeks before the screening period; Treatment with anti-ige, anti-IL-5, or anti-IL-5R within 4 weeks before the screening period; Inhaled ICS+LABA+ long-acting anticholinergic agent (LAMA) for 4 weeks prior to the screening period 4. Allergy to macrolides; The presence of numerous other lung tissue destructive diseases, such as severe bronchiectasis or pulmonary tuberculosis; Anti-tuberculosis treatment is ongoing; QTc interval prolongation >480ms; Taking medications that interact with azithromycin, causing QTc prolongation or existing ECG abnormalities, may lead to arrhythmia; Women who are pregnant and lactating.